The long-term objective of this proposal is to develop new photoaffinity labels for the mu opioid receptor which will materially assist in the identification, characterization and sequencing of the mu receptor. The photoaffinity labels are designed to photolyze at about 35 nm to minimize photodestruction of the target receptor. One group of mu ligands will contain either a cyclohexenone or cyclohexadienone functionality and have not been employed previously for photolabelling of opioid receptors. The second group of compounds will consist of opiates with intrinsic photoreactivity. Preliminary experiments demonstrated that a codeinone derivative photolysis in methanol at 365 nm to give a new compound which has incorporated the elements of methanol. All target compounds will be submitted for receptor binding and in vitro and in vivo opioid activity. Ligands which photolabel the mu receptor will be radiolabelled for the purpose of tagging the receptor.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA001674-16
Application #
3206992
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1977-06-01
Project End
1993-07-31
Budget Start
1992-07-01
Budget End
1993-07-31
Support Year
16
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Rensselaer Polytechnic Institute
Department
Type
Schools of Arts and Sciences
DUNS #
002430742
City
Troy
State
NY
Country
United States
Zip Code
12180
Archer, S; Seyed-Mozaffari, A; Jiang, Q et al. (1994) 14 alpha,14' beta-[Dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis (7,8-dihydromorphinone) and 14 alpha,14' beta-[dithiobis[(2-oxo-2,1- ethanediyl)imino]]bis[7,8-dihydro-N-(cyclopropylmethyl)normorphinone]: chemistry and opioid binding properties. J Med Chem 37:1578-85
Simon, E J; Fan, L Q; Hiller, J M et al. (1993) Photoaffinity ligands for the mu opioid receptor. Life Sci 53:1173-8
Sebastian, A; Bidlack, J M; Jiang, Q et al. (1993) 14 beta-[(p-nitrocinnamoyl)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity. J Med Chem 36:3154-60
Jiang, Q; Seyed-Mozaffari, A; Archer, S et al. (1993) Pharmacological study of 14 beta-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normor phinone (N-CPM-TAMO). J Pharmacol Exp Ther 264:1021-7
Bidlack, J M; Kaplan, R A; Subbramanian, R A et al. (1993) Affinity labeling of the mu opioid receptor in bovine striatal membranes with [3H]-14 beta-(bromoacetamido)-7,8-dihydromorphine. Biochemistry 32:6703-11
Jiang, Q; Seyed-Mozaffari, A; Archer, S et al. (1993) Antinociceptive evaluation of 14 beta-(bromoacetamido)-7,8-dihydro- N(cyclopropylmethyl)-normorphinone in mice. Eur J Pharmacol 240:201-6
Jiang, Q; Seyed-Mozaffari, A; Archer, S et al. (1992) Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO). J Pharmacol Exp Ther 262:526-31
Archer, S; Medzihradsky, F; Seyed-Mozaffari, A et al. (1992) Synthesis and characterization of 7-nitrobenzo-2-oxa-1,3-diazole (NBD)-labeled fluorescent opioids. Biochem Pharmacol 43:301-6
Archer, S; Bidlack, J; Mulholland, G K (1990) Opium alkaloids and affinity labels. NIDA Res Monogr 96:21-34
Bidlack, J M; Frey, D K; Kaplan, R A et al. (1990) Affinity labeling of mu opioid receptors by sulfhydryl alkylating derivatives of morphine and morphinone. Mol Pharmacol 37:50-9

Showing the most recent 10 out of 14 publications